b cell lymphoma cancer | Spontaneous regression of large cell B lymphoma of palaisHard palate B cell lymphoma with spontaneous regression

Spontaneous regression of large cell B lymphoma of palaisHard palate B cell lymphoma with spontaneous regression

Summary
Introduction
Non-Hodgkin lymphomas are common cancers that can develop in the upper aero-digestive tract. We describe a case of a large B-cell palatine lymphoma with spontaneous clinical regression.

Box
A 58-year-old female patient presented with a sub-mucosal lesion of the hard palate. CT scan and magnetic resonance imaging revealed a lesion invading the right posterior palatine canal. At the second consultation, 15 days after performing the biopsy, the lesion had disappeared. PET Scan Proven the absence of lesion. Lymph node biopsy supported the diagnosis of large B-cell lymphoma.

Discussion
Large B-cell lymphoma of the hard palate is a rare disease. Only 27 cases have been described in the international literature. The anatomopathological analysis is often difficult to perform. The final diagnosis is often made by immunochemistry. The usual treatment is R-CHOP chemotherapy (cyclophosphamide, Adriamycin, vincristine, prednisone combined to rituximab) with a 5-year survival rate at 55%.

Summary
Introduction
Non-Hodgkin (NHL) lymphomas are frequent cancers that can be located at the Upper aero-digestive tract (VADS). We describe a spontaneously regressive, large-celled palatine B lymphoma.

Observation
A 58-year-old patient had a submucosal lesion of the hard palate. At the CT and MRI, the lesion invaded the right posterior palatine canal. Fifteen days after the biopsy, the lesion had disappeared as confirmed by positron emission tomography. A ganglionic biopsy finally made it possible to diagnose B lymphoma with large cells.

Discussion
The hard palate B-cell lymphoma is rare. Twenty-seven cases have been published. The anatomopathologic exam is often difficult to interpret. The definitive diagnosis is based on the immunomarquages. The reference treatment is the R-CHOP type chemotherapy (cyclophosphamide, Adriamycin, vincristine, prednisone) associated with the rituximab, with a five-year overall survival rate of 55%.